Warning: The NCBI web site requires JavaScript to function. more...
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis.
Thompson A, Brennan K, Cox A, Gee J, Harcourt D, Harris A, Harvie M, Holen I, Howell A, Nicholson R, Steel M, Streuli C.
Breast Cancer Res. 2008;10(2):R26. Epub 2008 Mar 27. Review.
Related citations
The problems with risk selection; scientific and psychosocial aspects.
Hartman AR.
Recent Results Cancer Res. 2005;166:125-44. Review.
Antiangiogenic therapy for metastatic breast cancer: current status and future directions.
Chan A.
Drugs. 2009;69(2):167-81. doi: 10.2165/00003495-200969020-00003. Review.
Breast cancer: new technologies for risk assessment and diagnosis.
Wright T, McGechan A.
Mol Diagn. 2003;7(1):49-55. Review.
Biomarkers for breast cancer.
Beenken SW, Bland KI.
Minerva Chir. 2002 Aug;57(4):437-48. Review.
Do we make optimal use of the potential of cancer prevention?
Greenwald P, Dunn BK.
Recent Results Cancer Res. 2009;181:3-17. Review.
Nursing intervention and older adults who have cancer: specific science and evidence based practice.
Bourbonniere M, Kagan SH.
Nurs Clin North Am. 2004 Sep;39(3):529-43. Review.
Biological therapy of breast cancer: recent clinical applications.
Baar J.
Curr Opin Investig Drugs. 2007 Dec;8(12):987-95.
New molecular targets of breast cancer therapy.
Sauer G, Deissler H, Kurzeder C, Kreienberg R.
Strahlenther Onkol. 2002 Mar;178(3):123-33. Review.
Gene targets of antisense therapies in breast cancer.
Yang DC, Elliott RL, Head JF.
Expert Opin Ther Targets. 2002 Jun;6(3):375-85. Review.
Molecular targets as therapeutic strategies in the management of breast cancer.
Russo SM, Ove R.
Expert Opin Ther Targets. 2003 Aug;7(4):543-57. Review.
Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool.
Gasparini G, Harris AL.
J Clin Oncol. 1995 Mar;13(3):765-82. Review.
Antiangiogenic strategies, compounds, and early clinical results in breast cancer.
Morabito A, Sarmiento R, Bonginelli P, Gasparini G.
Crit Rev Oncol Hematol. 2004 Feb;49(2):91-107. Review.
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.
Johnson WD, Diaz RM, Flanders WD, Goodman M, Hill AN, Holtgrave D, Malow R, McClellan WM.
Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001230. Review.
The changing landscape of breast cancer clinical research. ESMO-Award Lecture, ECCO-9 Hamburg, 18 September 1997.
Piccart MJ.
Ann Oncol. 1998 Feb;9(2):133-8.
High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer.
Rennstam K, Hedenfalk I.
Breast Cancer Res. 2006;8(4):213. Review.
Cancer therapeutics: understanding the mechanism of action.
Cattley RC, Radinsky RR.
Toxicol Pathol. 2004 Mar-Apr;32 Suppl 1:116-21. Review.
Molecularly targeted therapeutics for breast cancer.
Hussain SA, Palmer DH, Spooner D, Rea DW.
BioDrugs. 2007;21(4):215-24. Review.
Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.
Thirthagiri E, Lee SY, Kang P, Lee DS, Toh GT, Selamat S, Yoon SY, Taib NA, Thong MK, Yip CH, Teo SH.
Breast Cancer Res. 2008;10(4):R59. Epub 2008 Jul 16.
["Screening" in special situations. Assessing predictive genetic screening for hereditary breast and colorectal cancer].
Jonas S, Wild C, Schamberger C.
Z Arztl Fortbild Qualitatssich. 2003 Feb;97(1):67-71. German.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on